When it comes to dissolution testing, research is focusing on ways to extend its reach, improve in-vitro and in-vivo correlation, and make real-time release testing a reality. Studying how a drug ...
New York, NY, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Pharmaceutical Dissolution Testing Services Market Share, Size, Trends, Industry ...
Advances in dissolution testing technology have been one of the biggest breakthroughs in solid dosage form testing over the last decade. The full version of this analytical technologies feature can be ...
The Pharmaceutical Dissolution Testing Services Market is poised for significant growth, with a projected market value of US$1.53 billion by 2033. This surge represents a substantial increase from the ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation ...
In the manufacture of solid dosage forms, the rate at which the active pharmaceutical ingredient (API) is dissolved into solvents simulating the digestive tract fluids is determined with dissolution ...
The British Pharmacopoeia on Monday released its response to its consultation on dissolution testing and announced its plans to update its approach within its product monographs. The British ...
The dissolution profile of inhaled drugs underpins therapeutic efficacy and is an area of increasing regulatory scrutiny, particularly for the demonstration of bioequivalence in a generic. The new ...
Teva is voluntarily recalling a single lot of Anagrelide Capsules, USP 0.5mg, due to dissolution failure that was detected during a routine stability test. Teva is voluntarily recalling a single lot ...
When you get a headache, you want something that delivers immediate relief. When pollen levels spike, sufferers want an allergy medication that works all day. These types of products are designed to ...
The Kathmandu Post on MSN
DDA took 11 months to test substandard drug. Patients may have already taken it
The Department of Drug Administration (DDA) has recalled a third-generation antibiotic, Levoflox-500 tablet, after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback